BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 29035450)

  • 1. Imbalance between Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Promotes Invasion and Metastasis of Head and Neck Squamous Cell Carcinoma.
    Stanciu AE; Zamfir-Chiru-Anton A; Stanciu MM; Popescu CR; Gheorghe DC
    Clin Lab; 2017 Oct; 63(10):1613-1620. PubMed ID: 29035450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
    Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
    J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas.
    Görögh T; Beier UH; Bäumken J; Meyer JE; Hoffmann M; Gottschlich S; Maune S
    Head Neck; 2006 Jan; 28(1):31-9. PubMed ID: 16265652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of MMP-2, -9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas.
    Ondruschka C; Buhtz P; Motsch C; Freigang B; Schneider-Stock R; Roessner A; Boltze C
    Pathol Res Pract; 2002; 198(8):509-15. PubMed ID: 12389993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Matrix metalloproteinase 2 and 9 as the factor of head and neck tumor metastasis].
    Kondakova IV; Klisho EV; savenkova OV; Kakurina GV; Choĭnzonov EL; Shishkin DA; Mukhamedov MP
    Biomed Khim; 2008; 54(5):555-60. PubMed ID: 19105397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
    Zhang S; Li L; Lin JY; Lin H
    World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
    Maeta H; Ohgi S; Terada T
    Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
    Zhou CY; Yao JF; Chen XD
    Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression and significance of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in non-melanoma skin cancer].
    Fu XR; Zhang C; Chen CY; Zhang L; Wang LX; Wang BH; Liu XY; Zhang MZ
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):369-73. PubMed ID: 22883459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma--tissue immunoreactivity predicts aggressive clinical course.
    Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
    Mod Pathol; 2006 Feb; 19(2):208-17. PubMed ID: 16424893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase imbalance in inguinal hernia formation.
    Antoniou GA; Tentes IK; Antoniou SA; Simopoulos C; Lazarides MK
    J Invest Surg; 2011; 24(4):145-50. PubMed ID: 21675849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients.
    Lanchou J; Corbel M; Tanguy M; Germain N; Boichot E; Theret N; Clement B; Lagente V; Malledant Y
    Crit Care Med; 2003 Feb; 31(2):536-42. PubMed ID: 12576963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck.
    O-Charoenrat P; Rhys-Evans PH; Eccles SA
    Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):813-20. PubMed ID: 11448356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2.
    Tayebjee MH; Lip GY; Blann AD; Macfadyen RJ
    Thromb Res; 2005; 115(3):205-10. PubMed ID: 15617743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis.
    Sutinen M; Kainulainen T; Hurskainen T; Vesterlund E; Alexander JP; Overall CM; Sorsa T; Salo T
    Br J Cancer; 1998 Jun; 77(12):2239-45. PubMed ID: 9649139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis.
    Katayama A; Bandoh N; Kishibe K; Takahara M; Ogino T; Nonaka S; Harabuchi Y
    Clin Cancer Res; 2004 Jan; 10(2):634-40. PubMed ID: 14760086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer.
    Jobim FC; Xavier NL; Uchoa DM; Cruz DB; Saciloto M; Chemello N; Schwartsmann G
    Braz J Med Biol Res; 2009 Oct; 42(10):979-87. PubMed ID: 19787153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.